(By the way - these can be remembered by SELL-D!) Theres also a similar class of medications called dual GLP-1/GIP receptor agonists
They mimic the natural hormone GLP-1, which: Stimulates insulin secretion Suppresses glucagon (a hormone that raises blood sugar) Delays gastric emptying (keeping you full longer) Reduces appetite via brain satiety centers This combination of effects leads to significant weight loss, improved blood sugar control, and reduced cardiovascular risks, especially when combined with lifestyle and plant-based care

Also, although there is clinical event reduction data at lower doses in diabetics, getting these data at higher doses in obesity will be very important, especially to support insurers paying a substantial part of the cost of this medication. Also important to learn, Neeland said, is that what is not known, and is not able to be known from the STEP program, are whether there are select benefits in patients with excess visceral adiposity as opposed to excess subcutaneous fat where the fat is in the body, is that related to the weight-loss response, and is it, potentially, then related to the CV benefit? Individualized interventions coupled with the right pharmacotherapy are key, though that often involves trial and error, Stanford said
Potential Health Benefits: Losing weight can have numerous health benefits, including reduced risk of chronic diseases such as heart disease and diabetes
Generally, tirzepatide seems to have an edge over semaglutide, with people losing up to 22.5% of their weight, compared to an average of 17% with semaglutide